Progress in Allosteric Database.

An allosteric mechanism refers to the biological regulation process wherein macromolecules propagate the effect of ligand binding at one site to a spatially distant orthosteric locus, thus affecting activity. The theory has remained a trending topic in biology research for over 50 years, since the understanding of allostery is fundamental for gleaning numerous biological processes and developing new drug therapies. In the past two decades, the allosteric paradigm has evolved into more descriptive models, with ever-expanding amounts of experimental data pertaining to newly identified allosteric molecules. The AlloSteric Database (ASD, accessible at http://mdl.shsmu.edu.cn/ASD ), which is a comprehensive knowledge repository, has provided the public with integrated information encompassing allosteric proteins, modulators, sites, pathways, and networks to investigate allostery since 2009. In this chapter, we introduce the history and usage of the ASD and give attention to specific applications that have benefited from the ASD.

[1]  Jing Lu,et al.  Are there physicochemical differences between allosteric and competitive ligands? , 2017, PLoS Comput. Biol..

[2]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[3]  Ruth Nussinov,et al.  The design of covalent allosteric drugs. , 2015, Annual review of pharmacology and toxicology.

[4]  Shaoyong Lu,et al.  Recent computational advances in the identification of allosteric sites in proteins. , 2014, Drug discovery today.

[5]  M. Schumacher,et al.  Allosteric intermediates indicate R2 is the liganded hemoglobin end state. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[7]  J. Albert,et al.  Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. , 2017, Bioorganic & medicinal chemistry letters.

[8]  Arthur Christopoulos,et al.  Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.

[9]  X. Xie,et al.  Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5 , 2017, The AAPS Journal.

[10]  M. Perutz,et al.  Structure of Hæmoglobin: A Three-Dimensional Fourier Synthesis at 5.5-Å. Resolution, Obtained by X-Ray Analysis , 1960, Nature.

[11]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[12]  Nikolay V Dokholyan,et al.  Controlling Allosteric Networks in Proteins. , 2013, Chemical reviews.

[13]  Ozlem Keskin,et al.  Ras Conformational Ensembles, Allostery, and Signaling. , 2016, Chemical reviews.

[14]  N. Shibayama,et al.  Capturing the hemoglobin allosteric transition in a single crystal form. , 2014, Journal of the American Chemical Society.

[15]  Shuai Li,et al.  ASD v2.0: updated content and novel features focusing on allosteric regulation , 2013, Nucleic Acids Res..

[16]  Cody J. Wenthur,et al.  Drugs for allosteric sites on receptors. , 2014, Annual review of pharmacology and toxicology.

[17]  N. Goodey,et al.  Allosteric regulation and catalysis emerge via a common route. , 2008, Nature chemical biology.

[18]  D. Tobi.  Dynamics and allostery of the ionotropic glutamate receptors and the ligand binding domain , 2016, Proteins.

[19]  R. Nussinov,et al.  Allosteric conformational barcodes direct signaling in the cell. , 2013, Structure.

[20]  J. Changeux,et al.  Allosteric Mechanisms of Signal Transduction , 2005, Science.

[21]  R. Nussinov,et al.  Allostery in Disease and in Drug Discovery , 2013, Cell.

[22]  P. Rogers,et al.  A third quaternary structure of human hemoglobin A at 1.7-A resolution. , 1992, The Journal of biological chemistry.

[23]  A G Murzin,et al.  SCOP: a structural classification of proteins database for the investigation of sequences and structures. , 1995, Journal of molecular biology.

[24]  Burak Erman,et al.  The gaussian network model: precise prediction of residue fluctuations and application to binding problems. , 2006, Biophysical journal.

[25]  Jens Meiler,et al.  Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential , 2011, Neuropharmacology.

[26]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[27]  V. Hilser,et al.  The ensemble nature of allostery , 2014, Nature.

[28]  X. Chen,et al.  Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs , 2015, Molecules.

[29]  E. Gouaux,et al.  Structure and symmetry inform gating principles of ionotropic glutamate receptors , 2017, Neuropharmacology.

[30]  Shaoyong Lu,et al.  Harnessing Allostery: A Novel Approach to Drug Discovery , 2014, Medicinal research reviews.

[31]  Shuai Li,et al.  ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks , 2015, Nucleic Acids Res..

[32]  Ian Sillitoe,et al.  The CATH classification revisited—architectures reviewed and new ways to characterize structural divergence in superfamilies , 2008, Nucleic Acids Res..

[33]  D. Koshland,et al.  Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.

[34]  Shaoyong Lu,et al.  Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions. , 2018, Journal of medicinal chemistry.

[35]  R. Nussinov,et al.  Unraveling structural mechanisms of allosteric drug action. , 2014, Trends in pharmacological sciences.

[36]  J. Changeux,et al.  Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation , 2016, Cell.

[37]  M. Congreve,et al.  Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. , 2017, Trends in pharmacological sciences.

[38]  Rommie E. Amaro,et al.  Computational approaches to mapping allosteric pathways. , 2014, Current opinion in structural biology.

[39]  Rob Leurs,et al.  Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.

[40]  A. Voet,et al.  Fragment based drug design: from experimental to computational approaches. , 2012, Current medicinal chemistry.

[41]  Diane Joseph-McCarthy,et al.  Fragment-Based Lead Discovery and Design , 2014, J. Chem. Inf. Model..

[42]  D. Tobi,et al.  Multiple Gaussian network modes alignment reveals dynamically variable regions: The hemoglobin case , 2014, Proteins.

[43]  Mark Gerstein,et al.  Normal modes for predicting protein motions: A comprehensive database assessment and associated Web tool , 2005, Protein science : a publication of the Protein Society.

[44]  E. Gouaux,et al.  Mechanisms for Activation and Antagonism of an AMPA-Sensitive Glutamate Receptor Crystal Structures of the GluR2 Ligand Binding Core , 2000, Neuron.

[45]  Gerard J. P. van Westen,et al.  Chemical, Target, and Bioactive Properties of Allosteric Modulation , 2014, PLoS Comput. Biol..

[46]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[47]  Ying Liu,et al.  Toward Understanding Allosteric Signaling Mechanisms in the ATPase Domain of Molecular Chaperones , 2010, Pacific Symposium on Biocomputing.

[48]  Jianrong Xu,et al.  AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses , 2018, Nucleic Acids Res..

[49]  Rommie E. Amaro,et al.  Emerging Computational Methods for the Rational Discovery of Allosteric Drugs , 2016, Chemical reviews.

[50]  Gareth Williams.  Elastic network model of allosteric regulation in protein kinase PDK1 , 2010, BMC Structural Biology.

[51]  J. Kemp,et al.  Ionotropic and metabotropic glutamate receptor structure and pharmacology , 2005, Psychopharmacology.

[52]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[53]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[54]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[55]  Qi Wang,et al.  Toward understanding the molecular basis for chemical allosteric modulator design. , 2012, Journal of Molecular Graphics and Modelling.

[56]  Ruth Nussinov,et al.  Introduction to Protein Ensembles and Allostery. , 2016, Chemical reviews.

[57]  Ivet Bahar,et al.  iGNM 2.0: the Gaussian network model database for biomolecular structural dynamics , 2015, Nucleic Acids Res..

[58]  Geng Wu,et al.  ASD: a comprehensive database of allosteric proteins and modulators , 2010, Nucleic Acids Res..

[59]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[60]  K. Gregory,et al.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. , 2016, Chemical reviews.

[61]  M. Karplus,et al.  Unsuspected pathway of the allosteric transition in hemoglobin , 2011, Proceedings of the National Academy of Sciences.

[62]  Thomas Seidel,et al.  Strategies for 3D pharmacophore-based virtual screening. , 2010, Drug discovery today. Technologies.

[63]  A. Sobolevsky,et al.  Structure of an agonist-bound ionotropic glutamate receptor , 2014, Science.